ASH: Hematology

Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk

Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease

Iptacopan improved hemoglobin without transfusion versus current standard of care

European trial is "practice-changing as of today," says U.S. expert

Most complete responses lasted 24 months or longer after limited-duration glofitamab

Phase III study showed 58% reduction in the risk of death versus chemo alone

Data from St. Jude cohort show higher rates of neurocognitive impairment

No difference in live birth rates with or without blood thinner

Glycoprotein receptor inhibitor produces four times as many responses as placebo

Also less likely for patients on Medicare and Medicaid

Similar outcomes if patients went directly to transplant or received intensive salvage first

Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients

Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone

"We should eliminate these silly neutropenic diets," expert says